Relay drug shows early promise against rare blood vessel diseases
BioPharma Dive
While early, the findings suggest the therapy could be superior to Novartis Vijoice at treating vascular anomalies, a cluster of chronic conditions with few available treatments.
pharminent
May 19, 2026 (Last updated: May 21, 2026)
BioPharma Dive
While early, the findings suggest the therapy could be superior to Novartis Vijoice at treating vascular anomalies, a cluster of chronic conditions with few available treatments.
